ReviewMedComm2026
Liquid-Liquid Phase Separation in Viral Infection and Immunology.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid-liquid phase separation (LLPS) has emerged as a fundamental physicochemical principle that organizes macromolecules into dynamic, membraneless condensates. These assemblies are increasingly recognized as critical regulators of diverse cellular processes. Notably, both viruses and their hosts exploit LLPS to optimize their respective strategies for replication and defense, forming a dynamic interplay centered around phase separation. However, a comprehensive mechanistic understanding of how LLPS modulates the dynamic viral-host battle, and how this knowledge can be leveraged for therapeutic development, remains an active area of investigation. This review systematically explores the dual roles of LLPS in viral infection and antiviral immunity. We detail how viruses hijack LLPS to form replication factories and inclusion bodies that enhance entry, replication, and immune evasion. Conversely, we explore how host cells leverage LLPS to assemble potent immune signaling hubs, such as those nucleated by cGAS-STING, NLRP6 inflammasomes, and T/B-cell receptor microdomains, to amplify antiviral responses. Furthermore, we critically evaluate emerging therapeutic strategies that target these phase separation interfaces. By integrating recent advances across virology, immunology, and biophysics, this review establishes a unified framework for understanding and targeting LLPS in viral infectious diseases, offering new perspectives for future basic research and clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.